The 7 analysts offering 12-month price forecasts for Myriad Genetics Inc have a median target of 22.00, with a high estimate of 27.00 and a low estimate of 18.00. The median estimate represents a +2.95% increase from the last price of 21.37.
The current consensus among 9 polled investment analysts is to Hold stock in Myriad Genetics Inc. This rating has held steady since May, when it was unchanged from a Hold rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share $0.03
Reporting Date Aug 02
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.